A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancer

A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancer

Abstract Background Despite being a potentially attractive alternative molecular imaging modality due to wider availability and association with lethal disease in advanced prostate cancer, the role of fluorodeoxyglucose (FDG)- positron emission tomography (PET) at initial diagnosis compared to Prost...

Full description

Saved in:

Bibliographic Details
Main Authors:	Matthew J. Roberts, Natasha A. Roberts, Anita Pelecanos, John W. Yaxley, Simon J. D. Harley, Amila R. Siriwardana, Karla Cullen, Marita Prior, Karen Lindsay, Ian Vela, Anna Kuchel, Nattakorn Dhiantravan, Paul Thomas, David A. Pattison
Format:	Article
Language:	English
Published:	SpringerOpen 2025-07-01
Series:	EJNMMI Research
Subjects:	Prostate cancer Prostate-specific membrane antigen PSMA PET/CT 18F-FDG Cancer staging
Online Access:	https://doi.org/10.1186/s13550-025-01265-z
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Intra-Individual Comparisons of [18F]fluorodeoxyglucose and Prostate-Specific Membrane Antigen Positron Emission Tomography in Prostate Cancer Patients Across Different Disease States: New Insights into Disease Heterogeneity
by: Stephen McGeorge, et al.
Published: (2024-12-01)

Comparison of 18F-FDG and 68-PSMA-11 in PET for prostate cancer diagnosis
by: Natalia Fulle, et al.
Published: (2022-12-01)

Diagnostic value of dual-tracer PET/CT with [18F]FDG and PSMA ligands in prostate cancer: an updated systematic review
by: Cesare Michele Iacovitti, et al.
Published: (2025-07-01)

Head-to-head comparison of 68Ga-PSMA-11 and 18F-FDG in delayed PET/CT imaging in prostate cancer diagnosis
by: Biyao Hu, et al.
Published: (2025-04-01)

PSMA PET/CT scan reveals incidental meningioma in a prostate cancer patient
by: Venetia A. Florou, et al.
Published: (2025-05-01)

Which PSMA PET/CT interpretation criteria most effectively diagnose prostate cancer? a retrospective cohort study
by: Le Ma, et al.
Published: (2025-01-01)

PSMA response evaluation in follow-up PSMA-PET/CT after stereotactic ablative body radiotherapy (SABR) for oligometastases in prostate cancer
by: Anna-Lena Zang, et al.
Published: (2025-09-01)

Preclinical and clinical evaluation of [64Cu]Cu-PSMA-Q PET/CT for prostate cancer detection and its comparison with [18F]FDG imaging
by: Fei Chen, et al.
Published: (2025-04-01)

Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) in Initial Staging of Prostate Cancer Patients: The Beginning of a New Era
by: Juan Gómez Rivas, et al.
Published: (2025-05-01)

FDG PET/CT AND PSMA PET/CT IN MUSCULOSKELETAL SOFT TISSUE SARCOMAS
by: Ellen Nogueira Lima, et al.
Published: (2025-05-01)

The tumour sink effect on 68Ga-PSMA-PET/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study
by: Atefeh Zamanian, et al.
Published: (2025-07-01)

Unexpected discovery of hepatic cancer via 68Ga-PSMA PET/CT in the staging of prostate cancer
by: Radu Alexa, et al.
Published: (2025-06-01)

Metastasis directed radiotherapy versus standard of care for PSMA-PET diagnosed oligometastatic/oligoprogressive castration resistant prostate cancer
by: Laura Bauersachs, et al.
Published: (2025-07-01)

PSMA-PET-derived distance features as biomarkers for predicting outcomes in primary prostate cancer post-radical prostatectomy
by: Ruohua Chen, et al.
Published: (2025-07-01)

Comparing the Diagnostic Performance of [18F]PSMA‐1007 With [68Ga]Ga‐PSMA‐11 in PET/CT Imaging and Staging of Recurrent Prostate Cancer
by: Negar Abdi, et al.
Published: (2025-03-01)

[18F]PSMA-1007 PET for biochemical recurrence of prostate cancer, a comparison with [18F]Fluciclovine
by: Cato C. Loeff, et al.
Published: (2024-11-01)

Revolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents
by: Ute Hennrich, et al.
Published: (2025-06-01)

THE IMPACT OF 68GA-PSMA PET/CT ON THERAPY MANAGEMENT OF HIGH RISK PROSTATE CANCER
by: Duygu Has Şimşek, et al.
Published: (2021-01-01)

A fully automated AI-based method for tumour detection and quantification on [18F]PSMA-1007 PET–CT images in prostate cancer
by: Elin Trägårdh, et al.
Published: (2025-08-01)

PSMA PET/CT findings in high‐risk biochemical recurrence after local treatment of prostate cancer
by: Nicole Handa, et al.
Published: (2025-05-01)

Testing the diagnostic accuracy of a 68Ga-PSMA PET Scan in Early Biochemical Recurrence of Prostate Cancer
by: Vigna-Taglianti Riccardo, et al.
Published: (2024-10-01)

The impact of patient hydration and forced diuresis on [18F]PSMA-1007 urinary bladder uptake in PET/CT imaging
by: Aleksandr Igorevich Khalimon, et al.
Published: (2025-06-01)

Preoperative detection of extraprostatic tumor extension in patients with primary prostate cancer utilizing [68Ga]Ga-PSMA-11 PET/MRI
by: Clemens P. Spielvogel, et al.
Published: (2024-12-01)

The impact of preliminary patient hydration on physiological [18F]PSMA-1007 uptake in the urinary bladder on PET/CT
by: T. L. Antonevskaya, et al.
Published: (2024-06-01)

PSMA PET/CT for prostate cancer diagnosis: current applications and future directions
by: Zhengang Shen, et al.
Published: (2025-05-01)

Indications and Results for Ga-68 PSMA PET/CT in Patients with Biochemical Relapse of Prostate Cancer
by: Ivan Rogić, et al.
Published: (2024-01-01)

CT-SEGMENTED BONE SUV IN MULTIPLE MYELOMA: A COMPARATIVE STUDY OF ¹⁸F-FDG AND ⁶⁸GA-PSMA PET/CT
by: Alexandre Mercuri Barbosa, et al.
Published: (2025-05-01)

Biochemical failure-free survival of 18F-rhPSMA-7 and 18F-flotufolastat PET-guided salvage radiotherapy for patients with recurrent prostate cancer
by: Marco M. E. Vogel, et al.
Published: (2025-01-01)

Evaluation the Electronic Properties of Glu-Ureido Template via Ab-Initio Study as Target Specific for PSMA
by: Mohd. Faheem, et al.
Published: (2024-11-01)

Imaging and outcome correlates of ctDNA methylation markers in prostate cancer: a comparative, cross-sectional [⁶⁸Ga]Ga-PSMA-11 PET/CT study
by: Kilian Kluge, et al.
Published: (2025-02-01)

Case Report: Pituitary metastasis from prostate adenocarcinoma: an integrated diagnosis via 68Ga-PSMA PET/CT and methylome analysis
by: N. Bianchetto Wolf, et al.
Published: (2025-06-01)

COMPARISON BETWEEN 18F-PSMA AND 18F-FDG RADIOTRACERS FOR PET/CT IN THE EVALUATION OF PATIENTS WITH METASTATIC MELANOMA
by: Thiago Soare Rocha Alves, et al.
Published: (2025-05-01)

An Evaluation of the Diagnostic Accuracy of [68Ga]Ga-PSMA-11 vs. [18F]F-PSMA-1007 PET/CT for Lymph Node Staging in Patient Candidates for Radical Prostatectomy and Lymph Node Dissection: A Single Institutional Analysis
by: Paola Arena, et al.
Published: (2025-06-01)

Diagnostic value of 18F-PSMA-1007 PET/CT for predicting the pathological grade of prostate cancer
by: Xiao-Bo Niu, et al.
Published: (2024-12-01)

Synthesis of DOTA-Based <sup>43</sup>Sc Radiopharmaceuticals Using Cyclotron-Produced <sup>43</sup>Sc as Exemplified by [<sup>43</sup>Sc]Sc-PSMA-617 for PSMA PET Imaging
by: Jason P. Meier, et al.
Published: (2025-06-01)

LU-177-PSMA TREATMENT FOR METASTATIC PROSTATE CANCER – CASE EXAMPLES OF MIRACLE RESPONSES
by: K. Kairemo, et al.
Published: (2018-03-01)

An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer
by: Latifa Zekri, et al.
Published: (2020-12-01)

A population‐based analyses of the evolving management of cN1M0 prostate cancer in the PSMA‐PET era
by: Jennifer Ward, et al.
Published: (2025-07-01)

Preliminary clinical study of p-iodo benzoyl moiety-modified PSMA inhibitors and prospective comparison with 68Ga-PSMA-11
by: Jianpeng Cao, et al.
Published: (2025-06-01)

Development and validation of a visual nomogram for predicting clinically significant prostate cancer in negative mpMRI using 68Ga-PSMA PET/CT
by: Wei Hu, et al.
Published: (2025-07-01)